



PharmaMar establishes subsidiary in Belgium

Madrid, 16 November 2015: PharmaMar (MSE:PHM) has announced the opening of a new subsidiary in Brussels (Belgium) to strengthen the commercial team operating in the Benelux countries (Belgium, The Netherlands and Luxembourg). This enhances the Company's presence in Europe, one of the world's leading oncology markets.

With this new subsidiary in Belgium, PharmaMar now has a presence, with its own structure, in seven European countries. The other subsidiaries are located in Italy, Germany, France, Switzerland, Spain and the United Kingdom, consolidating the Company's business and distribution model.

Luis Mora, General Manager of PharmaMar's oncology unit: *"This new subsidiary is a continuation of our expansion strategy and also enables us to operate directly in one of Europe's principal markets. It is vital for us to have our own teams in certain European countries so as to offer the best service to our customers."*

Cancer incidence in Belgium, The Netherlands and Luxembourg

According to Belgian Cancer Registry data, 65,269 new cases of cancer were detected in Belgium in 2012, and it is estimated that around one in three men and one in four women will suffer this disease before the age of 75. The most prevalent types of cancer in Belgium are prostate, lung and colorectalⁱ.

As for The Netherlands, the World Health Organisation (WHO) reports that 93,448 new cases of cancer were diagnosed in 2012. The three most common cancers types in men were prostate, colorectal and lung cancer, while in women they were breast, colorectal and lung cancerⁱⁱ.

According to the WHO, cancer was the second most frequent cause of death in Luxembourg in 2012, behind cardiovascular diseaseⁱⁱⁱ. The three most common cancer types were: prostate, colorectal and lung cancer, among men, and breast, uterine and colorectal, among women^{iv}.



About PharmaMar

Headquartered in Madrid, PharmaMar is a world-leading biopharmaceutical company in the discovery and development of innovative marine-derived anticancer drugs. The company has an important pipeline of drug candidates and a robust R&D oncology program. PharmaMar develops and commercializes YONDELIS® in Europe and has other three clinical-stage programs under development for several types of solid and hematological cancers, PM1183, plitidepsin, and PM60184. PharmaMar is a global biopharmaceutical company with subsidiaries in Germany, Italy, France, Switzerland, United Kingdom and the United States. PharmaMar fully owns other companies: GENOMICA, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and two other chemical enterprises, Zelnova and Xylazel. To learn more about PharmaMar, please visit us at www.pharmamar.com.

Disclaimer

This document is a press release, not a prospectus. This document does not constitute or form part of an offering or invitation to sell or a solicitation to purchase, offer or subscribe shares of the company. Moreover, no reliance should be placed upon this document for any investment decision or contract and it does not constitute a recommendation of any type with regard to the shares of the company.

Media Inquiries:

Paula Fdez. Alarcón – Media Relations (+34 638 79 62 15)
Phone: +34 918466000



Investor Relations:

Phone: +34 914444500

Or please visit our website at www.pharmamar.com

###

ⁱ [http://www.kankerregister.org/Les chiffres du cancer](http://www.kankerregister.org/Les_chiffres_du_cancer)

ⁱⁱ <http://eco.iarc.fr/eucan/Country.aspx?ISOCountryCd=528>

ⁱⁱⁱ http://www.who.int/nmh/countries/lux_en.pdf

^{iv} <http://eco.iarc.fr/eucan/Country.aspx?ISOCountryCd=442>